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Introduction
The transfer of inventions from academic institutions to private 
industry is a major driver of economic growth and human 
welfare. Broadcom, Google, Akamai, Yahoo, Biogen, Bose, and 
Genentech represent just a handful of pioneering companies with 
academic roots (Kenney, 2017). Indeed, many of today’s defin-
ing technologies originated in academic labs, including nuclear 
energy and the internet (Busbin, 1995; Manyika & Roxburgh, 
2011; Nelson & Byers, 2015).
Technology-driven progress demands not only the development 
of new inventions, but also their dissemination throughout 
society. Our national capacity to fuel growth and improve human 
well-being through new technologies depends on our ability to 
pass these technologies through a commercialization pipeline. 
This national need for an efficient and effective technology 
handoff between academia and industry motivated our analysis 
of the current United States (U.S.) academic technology transfer 
environment.
Leveraging data from the Association of University Technology 
Managers (AUTM) U.S. Licensing Activity Survey, we char-
acterized the performance of research organizations across 
different steps of the technology transfer process. Our findings 
indicate that the translational abilities of research organizations 
across the U.S. vary widely, with a small minority of institutions 
producing the vast majority of technological and economic 
benefits. To begin addressing this gap, we surveyed initiatives 
aimed at improving technology transfer and propose remedies 
for observed disparities in institutional performance.
Methods
Defining the commercialization pipeline
The AUTM Licensing Survey solicits responses annually from 
around 300 institutions, including universities, hospitals and 
research institutions, to quantify the total technology transfer 
activity at these institutions. These metrics are derived from a 
set of core questions that AUTM deems essential for assessing 
transfer and licensing activity. A detailed description of each 
metric from the AUTM survey data is given in Supplementary 
Table 1. We defined the “commercialization pipeline” (Figure 1) 
by identifying a set of key questions asked in each AUTM 
survey, and extracting relevant data from the 2010 to 2014 
AUTM surveys. We use this commercialization pipeline to 
measure and compare relative levels of technology transfer 
activity at different institutions, and at different steps along the 
pipeline. The distributions of each metric across every surveyed 
institution are visualized as linear and log histograms, as well as 
empirical cumulative distributions, in Supplementary Figure 1 
and Supplementary Figure 2.
Identification of top performing institutions
We ranked each institution from the AUTM Licensing Survey 
data by each step in the commercialization pipeline. Any 
institution ranked in the top 10 (about the top 5%) in at least 
one stage of the pipeline was included in the our list of top 
performing institutions. This resulting list of 25 institutions 
(approximately 12% of all surveyed institutions) was then sorted 







where N = 7 is the number of stages in the pipeline and R
i
 is 
the ranking of the institution in step i of the pipeline. We chose 
this scoring system to identify institutions with consistently 
high performance across the commercialization pipeline while 
avoiding heavily penalizing anomalous weak performances in just 
a single metric.
Calculation of the Gini coefficient
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The Gini coefficient is a measure of statistical dispersion used 
to assess inequality in a population. A high Gini coefficient 
indicates high levels of inequality where, in this case, a few 
institutions contribute a substantial amount of total translational 
activity. Conversely, a low Gini coefficient indicates that each 
institutions contributes an equal share.
Statistical analysis
Variance estimates (υ) for the Gini coefficient for each step were 














where N is the number of observations, G is the Gini coeffi-
cient when all observations are considered, and G
i
 is the Gini 
coefficient value when the ith observation is removed. The 
confidence intervals of the log-normal fits were computed to 
the 95% confidence levels using the Jacobian of the parameter 
Figure 1. Commercialization pipeline. Each step in this pipeline corresponds to a metric in the AUTM survey. We use the health of the 
pipeline as a proxy for the overall health of the U.S. technology transfer ecosystem.
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estimates assuming normally distributed residuals. All statistical 
analysis was performed in MATLAB 2016b (Mathworks, Natick, 
MA, USA).
Results
Inequality between institutions through pipeline
Our goal was to understand how much each institution 
contributed to each step of the commercialization pipeline and 
to determine any notable overall trends in U.S. technology 
transfer. Histograms (Supplementary Figure 1 and Supplemen-
tary Figure 2) of contributions from each institution along the 
commercialization pipeline reveal highly skewed distributions. 
The distributions of each metric are generally well approximated 
by a log-normal fit. Note that the x-axes is on a log scale and 
therefore the significant skew in the distribution is not immedi-
ately apparent. The effectiveness of a log-normal fit decreases 
towards the end of the commercialization pipeline (Startups 
and Adjusted Gross Income).
The majority of institutions contribute a small amount to 
overall technology transfer regardless of how activity is meas-
ured (Figure 2 and Supplementary Figure 3). Specifically, the top 
20% of institutions contribute over 60% of total commerciali-
zation activity. Importantly, this trend is robust to normaliza-
tion by research expenditures, which indicate that differences 
in research funding do not explain the gap in productivity 
(Supplementary Figure 3). In fact, the top 10% of institutions 
contribute over 40% of “startups per dollar of research expen-
ditures” and over 70% of “adjusted gross income per dollar of 
research expenditures”.
Highly performing institutions
We identified the 25 top-performing institutions by sorting all 
top-performing institutions by the average of their reciprocal 
ranking at each step in the commercialization pipeline (Table 1). 
Most organizations that perform well do so across the entire 
commercialization pipeline, indicating strong and broad tech-
nology transfer abilities (e.g. University of California and 
University of Texas Systems; MIT; and Stanford). On the other 
hand, some organizations excel in only specific parts of the 
commercialization pipeline (e.g. University of Washington 
in Licenses and Options Executed; California Institute of Tech-
nology in New Patent Applications; and University of Georgia 
in Licenses and Options Executed), which reveals focused, less- 
robust technology transfer capabilities.
Dispersion analysis
We extended this analysis by calculating the Gini coefficient, 
a measure of statistical dispersion that is often used to 
quantify income inequality (Gini, 1912). In this analysis, a low 
Gini coefficient indicates that each institution is contributing 
roughly equally to U.S. technology commercialization, whereas 
a high Gini coefficient indicates that a few institutions are 
producing the majority of the commercialization output.
Figure 2. Contribution by top 1%, top 20% and bottom 80% of institution to each step of the commercialization pipeline. A small 
number of institutions contribute to the majority of commercialization activity.
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Patents Issued (US) Licenses and 
Options Executed
Startups
University of California System 5364 1605 1117 359 261 66
University of Texas System 2508 772 357 173 155 24
Massachusetts Inst. of Technology (MIT) 1515 646 514 232 107 18
Stanford University 855 492 308 210 116 16
Johns Hopkins University 1540 417 400 72 132 10
University of Washington/Wash. Res. Foundation 1010 401 172 75 225 12
California Institute of Technology 426 389 565 149 51 10
University of Michigan 1257 363 152 106 115 11
UW-Madison/WARF 1113 378 129 153 63 6
University of Pennsylvania 886 386 196 78 107 15
Columbia University 737 356 230 86 82 15
University of Illinois, Chicago, Urbana 972 354 159 102 87 12
Massachusetts General Hospital 744 326 185 83 132 9
University of Florida 548 330 167 84 128 14
Cornell University 781 363 175 82 130 10
University of Utah 401 223 99 67 82 18
University of Georgia 307 163 56 34 157 3
Georgia Institute of Technology 741 364 228 79 72 10
Harvard University 812 377 213 66 78 9
University of Colorado 809 239 297 39 53 9
University System of Maryland 998 292 180 64 38 9
Duke University 845 212 127 47 118 6
University of Pittsburgh 755 264 89 49 124 6
University of South Florida 441 177 89 89 58 9
Johns Hopkins University Applied Physics 
Laboratory
1101 219 59 18 29 3
As shown in Figure 3 and Supplementary Figure 3, high levels 
of inequality exist throughout the pipeline. For context, the Gini 
coefficient of patents issued in the U.S. is above 60%, while 
the Gini coefficient of all U.S. household income is 48% (U.S. 
Census Bureau). We believe this indicates that the majority of 
U.S. research organizations have significant untapped commer-
cialization potential, the full realization of which could lead to 
new technologies and, overall, improved U.S. productivity.
Improving the pipeline
Many of the top performing institutions have invested significant 
effort and resources in supporting entrepreneurs at each stage 
of the commercialization pipeline. Top performing institutions 
have ensured continuity in their support structure to enable the 
efficient and effective translation and development of both insti-
tute-owned and student-created intellectual property. Table 2 
highlights active programs at MIT and Harvard, two top perform-
ing translational institutions. Our summary of these initiatives 
span university incubators, student organizations, university ven-
ture capital funds and business plan competitions (Table 2).
The overview of successful programs (Table 2) provides a blue-
print for universities that would like to foster improved technol-
ogy transfer and innovation. While some of these programs would 
require a significant undertaking on the part of the university, 
many can be achieved in a straightforward and lightweight manner 
via the support of student-led activities and partnership with 
government and private organizations. Examples of grassroot 
student groups that have launched many new programs exist at 
both MIT and Harvard. For instance, the MIT Biotech Group 
group has partnered with the MIT Alumni Angels of Boston to 
launch a life sciences-focused track to improve access to capital 
for early-stage startups. The Harvard Biotechnology Club runs an 
incubator program to develop and translate academic research. 
These programs represent student-led efforts that require little to 
no university expenditure or resources. For larger undertakings, 
university/corporate collaborations can provide an efficient 
means to achieve significant progress. A prime example of this 
is JLABS @ M2D2, the medical device incubator partnership 
between Johnson & Johnson and the University of Massachusetts 
Lowell (McCarthy et al., 2013).
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Figure 3. The Gini Coefficient for each stage in the commercialization pipeline, with G of 0% representing complete equality and 
G of 100% represents complete inequality. Error bars represent one standard deviation of uncertainty as estimated via jackknife resampling 
(Karagiannis & Kovacevic’, 2000; Yitzhaki, 1991).
Discussion
Expense, time, infrastructure, and the lack of partnerships are 
among the most common barriers to research commercialization 
and alleviating these bottlenecks allows more inventions to enter 
the marketplace (Vanderford et al., 2013). Programs to increase 
support for inventors at less well performing institutions to file 
disclosures, pursue patent prosecution, and seek licensing deals 
could significantly boost translational output. Sharing best 
practices from the leaders in technology commercialization may 
help bring more new technologies to market.
Supporting the commercialization pipeline
One salient feature of the top-performing institutions is their 
broad portfolio of commercialization-focused initiatives. Indi-
vidually, these projects typically target only a few steps on our 
commercialization pipeline (for example, business plan competi-
tions target the latter stages of the technology transfer process). 
However, the best performing universities have a large number 
of these efforts which, in aggregate, fully span the commerciali-
zation pipeline. This observation indicates a potential strategy 
for improvement of those less well served technology transfer 
pipelines; specifically, the cultivation of commercialization 
focused initiatives, such as incubators, business plan competitions, 
innovation prizes, law clinics, and student organizations. The 
value of these efforts goes beyond their immediate impact. For 
example, although when taken at face value, a business plan 
competition may seem to serve only the winning team, its merit 
truly stems from bringing together students, entrepreneurs, 
investors, and the media in a constructive setting. The resources 
required for such projects are small, and, given the disparity in 
commercialization, potential societal benefits are vast.
Outsourcing technology transfer to a third-party
A clear barrier to effective commercialization of university 
technology is the widespread lack of access to experienced, 
motivated, and well-resourced technology transfer offices (TTO). 
Many institutions are unable to support a comprehensive TTO, 
hampering efforts to introduce new technology into industry. 
The use of consultants can help alleviate some shortcomings, but 
faces its own barriers to widespread adoption (AUTM Technology 
Transfer Practice Manual).
Alternatively, a coalition of institutions could create a third- 
party technology licensing organization whose charter is to 
serve the technology transfer needs of those institutions. Like 
a sports agent, this third-party organization would use its exper-
tise to strike technology transfer deals between institutions and 
licensees, freeing universities to focus on their strengths. Funded 
directly by the institutions and, in part, by licensing revenue, this 
organization would have the necessary resources and freedom 
to hire top-tier technology transfer professionals who can effec-
tively interface between stakeholders in industry and in academia, 
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Table 2. Current programs at MIT and Harvard, two of the top-performing institutions, that strengthen the 






















Harvard Life Labs 
A 15,000-square-foot shared laboratory space for high-potential life 
sciences and biotech startups founded by Harvard
President’s Innovation Challenge 
A Campus-wide competition supporting student ventures through 
networking events, mentorship and funding
Harvard Catalyst Program 
An NIH funded center fostering a translational 
environment enabling collaboration and providing tools, 
training and technologies to investigators
Harvard Biotechnology Club 
A student organization that hosts events and provides 
educational services that allow members to explore the 




An institute-backed venture capital fund empowering disruptive 
technologies with the long-term capital, knowledge, and specialized 
equipment and labs they need to thrive
$100K Entrepreneurship Competition 
A student run entrepreneurship contest offering mentorship from venture 
capitalists, serial entrepreneurs, corporate executives, and attorneys, media 
exposure, prototyping funds, business plan feedback, and discounted 
services
Sloan Healthcare Innovation Prize 
A student run pitch competition supporting early-stage healthcare startups 
with feedback from industry professionals, pitch workshops, and funding
Sandbox 
An institute-backed seed funding for student-initiated 
entrepreneurship ideas, mentoring from both within and outside of 
MIT, and tailored educational experiences
Deshpande Center for Technological Innovation 
Support for bringing early-stage technologies to the 
marketplace in the form of breakthrough products and 
new companies through grants, mentorship, industry 
connections, and an annual symposium
MIT Biotechnology Group 
A student organization that buildings strong, symbiotic 
relationships between the MIT community, academia, and 
industry and serves the MIT community by facilitating 
development of knowledge, skills, networks, and 
experiences to prepare members for biotechnology-related 
careers
MIT Life Sciences Alumni Angels 
An alumni run angel investing network that 
supports MIT startups focused on the life 
sciences with funding, connections, and 
mentorship
while negotiating on behalf of the parent institutions. These 
teams would work to creatively package and license technologies 
to maximize their utility to society, as well as to assure that the 
parent institutions receive a fair return on their investment.
Operating outside of the university, this organization would be 
free to make decisions much more quickly than traditional TTOs. 
Similarly, its employees would be incentivized to work in the best 
interest of the parent institutions by ensuring the process is both 
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efficient and maximizes value for all stakeholders. This outsourced 
model of technology transfer speaks towards the latent need 
for more efficient, properly incentivized, and more widespread 
efforts to commercialize academic research and development 
efforts.
Conclusion
As the U.S. economy becomes increasingly driven by 
technological change, understanding and improving the com-
mercialization pipeline is critically important. The significant 
disparity in technology transfer performance is evident as the 
top few institutions produce a very large share of the country’s 
total technology transfer. We believe this disparity points to 
missed commercialization opportunities, which we as a society 
are paying for by missing out on potentially highly impactful 
innovations.
Supplementary material
Supplementary Figure 1. Histograms of each step in the commercialization pipeline shown in Figure 1. Insets show cumulative distribu-
tions, with shaded rectangles indicating the number of institutions necessary to reach 80% of total activity.
Click here to access the data.
 Supplementary Figure 2. Histograms of each step in the commercialization pipeline shown in Figure 1 with a log x-axis. Note that the 
x-axes is on a log scale and therefore the significant skew in the distribution is not immediately apparent.
Click here to access the data.
Supplementary Figure 3. Quantized and normalized distribution for each step in the commercialization pipeline. The shaded bars represent 
the percentage of the total of each category owned by institutions in percentiles indicated.
Click here to access the data.
Supplementary Table 1. Pipeline descriptions.
Click here to access the data.
Data availability
The AUTM Licensing Activity Survey data are available on the 
organization’s website (https://www.autm.net/resources-surveys/
research-reports-databases/licensing-surveys/) by fee or institu-
tional subscription/membership. As such, the raw data analyzed 
for this study cannot be provided in the context of this article. 
The 2010–2014 survey data used for this study was obtained as 
part of an institutional membership (University of Kentucky).
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